# A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

> **NCT06144697** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 267 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** BMS-986465
- **OTHER:** Placebo
- **DRUG:** Pegasys
- **DRUG:** Famotidine

## Key facts

- **NCT ID:** NCT06144697
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-29
- **Primary completion:** 2024-10-16
- **Final completion:** 2024-10-16
- **Target enrollment:** 267 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06144697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06144697, "A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06144697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*